Peptides AcademyEvery Peptide. Every Trial. Zero Hype.
The independent peptide reference. Every clinical claim links to PubMed. Every peptide is scored on a transparent 0-100 evidence scale. Zero affiliate links.
Free calculator · 14 peptide presets · every claim linked to PubMed
Every peptide graded on a transparent 0-100 scale
Scored across 4 factors (human trials, preclinical replication, safety, mechanism clarity). See the scoring methodology →
What Are Peptides?
Peptides are short chains of amino acids — between 2 and 50 residues — linked by peptide bonds. They act as signaling molecules: hormones like GLP-1 and GHRH, neuropeptides, growth factors. Some are produced by the body; others are engineered analogs with extended half-life (semaglutide, tirzepatide, tesamorelin); some are novel synthetic sequences used primarily in preclinical research (BPC-157, TB-500). This site covers them all with the same evidence lens.
FDA-approved or late-stage clinical candidates with published phase-3 data. Semaglutide, tirzepatide, tesamorelin, liraglutide. This is where the evidence is strongest and effect sizes are largest.
Amino acid sequence
Every peptide begins with a defined amino acid sequence — from GHK's three residues to tirzepatide's 39.
Structural engineering
Clinical peptides are chemically modified — fatty-acid tails, D-amino-acid substitutions, cyclization — to resist degradation and extend half-life.
Receptor binding
The sequence dictates which receptor the peptide binds — GLP-1R, GHRH-R, GHSR, MC4R. Receptor choice drives the biological effect.
Physiological signal
Downstream cascades produce the observable outcome — GH release, appetite suppression, tissue repair, collagen synthesis, glycemic control.
Peptides Cataloged
PubMed Sources
Peptide Calculators
Transparent Methodology
What Peptides Actually Do
A reality check on peptide effect sizes, grouped by what the evidence supports today.
Weight Loss (Large Effect)
Semaglutide and tirzepatide produce 15–22% mean body-weight reduction in controlled trials. The largest non-surgical effect ever observed.
Cardiovascular Risk (Validated)
SELECT (2023) showed semaglutide reducing major adverse cardiovascular events by 20% in overweight adults without diabetes.
Visceral Fat (Moderate)
Tesamorelin produces roughly 15 to 20% visceral-adipose-tissue reduction on CT imaging. A specific, reproducible effect.
Tissue Repair (Preclinical)
BPC-157 and TB-500 accelerate tendon, ligament, and muscle healing in rodent injury models. Human data is limited but mechanism is plausible.
Skin Remodeling (Modest)
GHK-Cu has decades of dermatology research. Measurable but modest effects on fine lines, photoaging, and wound healing.
Longevity Endpoints (Speculative)
Epitalon, MOTS-c, and bioregulator peptides have interesting mechanisms but no robust long-term human trials with mortality endpoints.
Browse by Peptide Class
Every peptide here is grouped by its mechanism class — not by the marketing category it's sold under.
Clinical & Research Brands
From Novo Nordisk and Lilly's FDA-approved GLP-1 and GIP agents to research-grade lyophilized supply.
Featured Peptides
Latest Analysis & Tier Lists
Explore Peptide Topics
From peptide-bond chemistry to GLP-1 trial readouts — the complete knowledge map.
Goals
Administration & Protocols
Stacks
Frequently Asked Questions About Peptides
Quick answers. Longer ones in the full FAQ.
What is a peptide?
A peptide is a short chain of amino acids — typically 2 to 50 residues — connected by peptide bonds. Peptides sit between individual amino acids and full proteins and act primarily as signaling molecules.
See the 2026 peptide tier listGet alerted the day STEP-6 reads out
We summarize every major peptide trial within 48 hours of publication. One email per week. Unsubscribe anytime. No affiliate links, ever.